What We're Reading: Page 183
Industry reads hand-picked by our editors
Mar 15, 2021
-
Nature Biotechnology
The next 25 years
-
Reuters
Money, talent flowing into mRNA sector after COVID-19 success
-
Financial Times
Insitro raises $400M for machine learning drug discovery push
-
Boston Business Journal
Indian biopharma spins out Cambridge oncology startup Bicara
Mar 12, 2021
-
The New York Times
The U.S. Is Sitting on Tens of Millions of Vaccine Doses the World Needs
-
Evaluate Vantage
After US approval Aveo faces a monumental task
-
STAT
Reining in drug patents isn't a silver bullet against high drug prices
-
FierceBiotech
Lilly rejoins KRAS race with swipe at Amgen and Mirati, plans 2021 clinical trial
Mar 11, 2021
-
Reuters
Insider alleges Eli Lilly blocked her efforts to sound alarms about U.S. drug factory
-
Bloomberg
J&J Vaccine Rollout Slowed by Shifting State Strategies
-
Evaluate Vantage
Gilead challenges Viiv in heavily treated HIV
-
Endpoints News
Aveo Oncology gets the long-awaited greenlight to market tivozanib — 9 years after filing its first NDA
Mar 10, 2021
-
Bloomberg
Biden Duo's Nudge Eased Merck-J&J Logjam to Speed Vaccine Output
-
NPR
In The '24th Mile' Of A Marathon, Fauci And Collins Reflect On Their Pandemic Year
-
The Sunday Times
GlaxoSmithKline doubles cash paid to doctors for promoting its drugs
-
In the Pipeline
Drug Approvals Over the Last Ten Years
Mar 09, 2021
-
The Boston Globe
For Biogen, it’s been a rough ride
-
The New York Times
Pandemic Forces F.D.A. to Sharply Curtail Drug Company Inspections
-
The Atlantic
The Differences Between the Vaccines Matter
Mar 08, 2021
-
The New York TImes
How Emergent BioSolutions Put an ‘Extraordinary Burden’ on the U.S.’s Troubled Stockpile
-
Financial Times
Pharma groups spend billions to tap into booming China healthcare
-
The Wall Street Journal
Russian Disinformation Campaign Aims to Undermine Confidence in Pfizer, Other Covid-19 Vaccines, U.S. Officials Say
-
STAT
How IBM's audacious plan to 'change the face of health care' fell apart